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Fig. 1. Brigh21st December 2005aryotype 46, XY — no abnormalities detected (Fig. 2)
ex Male (Fig. 3)
luripotent YES — by Nanog, Oct4, Tra1-60, and SSEA4 staining (Fig. 4)
as well as tri-lineage teratoma formation (Fig. 5), Pluritest (Fig. 6)
and Alkaline Phosphatase stain positivity (Fig. 7)isease status Unaffected
terility The cell line is tested and found to be negative for Mycoplasma
and any visible contamination (Fig. 8)
ibling lines
availableYES — ESI017; ESI014; Genea048 (XY trisomy 5
NIHhESC-12-0152, SCSC14-38)Fig. 2. CGH array analysis certiﬁcation.3. Materials and methods
3.1. Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was manu-
ally removed using a small blade. The embryo was bisected and both
ICM and trophectoderm were plated onto mitomycin C inactivated
GMP grade (Ortec) human feeders (plated 200,000 cells per organ cul-
ture dish — 69,204 cells/cm2) in 20% knockout serum in standard
hESC culture medium with 50 ng/mL Fgf2 (Amit et al., 2000). CGH and
karyotypingwere performed at theﬁrst cryobanking step from ICMout-
growthsmaintained on feeders. This processwasperformed underGMP
conditions, identical to those used in the creation of Embryonic Stem
Cell International's GMP hESC lines (Crook et al., 2007), however not
under a GMP control and documentation process. Cells were then enzy-
matically passaged as single cells in M2 pluripotent cell maintenance
medium (Genea Biocells) and CGH/karyotyping repeated, immunoﬂuo-
rescent pluripotent marker staining, Pluritest and sterility testing
performed.
3.2. Genetic analysis
CGH and DNA proﬁling were performed after acquisition of sufﬁ-
cient cell numbers from derivation and then again following the
thawing of banked vials of frozen stem cells (passage 17: 14 on feeders,
3 enzymatic), ensuring consistency in the genetic proﬁle. CGHwas used
to screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and dupli-
cations. Microarray analysis was performed using 8X 60k ISCA formattﬁeld morphology of Genea002 on human inactivated feeders.(Sure printG3, Agilent)with average 70kbprobe spacing. DNAproﬁling
using DNA Devyser Compact v3 QF-PCR method was used to study the
Allele pattern for the analysis of STR markers.
4. Pluripotency assessment
1. Immunoﬂuorescence: Passage 16 (14 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150; Tra1-60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. Teratoma formation: Passage 38; Genea002 were injected intramus-
cularly to immuno-deﬁcient mice and resultant teratomas excised,
ﬁxed, sectioned and stained for assessment of tissues from each of
the embryonic germ layers.
3. Pluritest: Passage 17 (14 on feeders, 3 enzymatic); RNAwas collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).
4. Alkaline Phosphatase: Passage 10; Genea002 were stained as per
manufacturers protocol using theMerckMillipore Alkaline Phospha-
tase Detection Kit (SCR004).
5. Sterility testing
1. Mycoplasma: Passage 20; testing was performed as per
manufacturer's instructions using theMycoAlertMycoplasmaDetec-
tion Kit from LONZA.Fig. 3. STR analysis certiﬁcation.
Fig. 4. Percentage of cells expressing SSEA4, Nanog, Oct3/4 and Tra1/60 as detected by
immunoﬂuorescence.
157B. Dumevska et al. / Stem Cell Research 16 (2016) 155–1582. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell Pro-
duction Team.Fig. 5. Teratoma formation and
Fig. 6. Plur6. Veriﬁcation and authentication
6.1. Ethics/consents
Ethics approval for the project (‘Development of human embry-
onic stem cells from excess ART embryos’) was obtained from the
Genea Ethics Committee on 21 February 2001. Excess ART embryos
were fully consented for stem cell derivation by all responsible
people through an informed consent process (signed de-
identiﬁed consent form can be provided upon request). Donors
have received no payment or ﬁnancial beneﬁts for their donation.
Genea002 has been derived from a donated, fully commercially
consented human embryo, originally created by assisted reproduc-
tion technology (ART) for the purpose of procreation, under the
Australian National Health and Medical Research Council
(NHMRC) licence 309703. This licence was issued to GENEA on 16
April 2004. More information about the licence can be obtained
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The derived stem cell line, Genea002, morphologically displays
adherent monolayer of compact cells in well-deﬁned colonies
with high nuclear to cytoplasmic ratio and prominent nucleoli
(Fig. 1).
6.3. Genetic analysis
The cell line has been tested by CGH, which demonstrated 46,
XY karyotype (Fig. 2), consistent with original derivation. Analysis of





Genea002 is pluripotent by:
1. immunoﬂuorescence with 75% Nanog positive, 93% Oct4 positive,
83% Tra1-60 positive, and 98% SSEA4 positive (Fig. 4).
2. teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 5).Fig. 8. Sterility testing.
Fig. 7. Alkaline Phosphatase staining.3. Pluritest with a 24.55 pluripotency score and 1.39 Novelty score
(Fig. 6).
4. Alkaline Phosphatase stain positivity (Fig. 7).
6.6. Sterility
The cell line is tested and found to be negative for Mycoplasma and
any visible contamination (Fig. 8).
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